[1]胡平华,黄 勤,李志华.含卡培他滨方案一线或后线治疗晚期乳腺癌的效果对比[J].医学信息,2018,(22):142-144.[doi:10.3969/j.issn.1006-1959.2018.22.041]
 HU Ping-hua,HUANG Qin,LI Zhi-hua.Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy[J].Medical Information,2018,(22):142-144.[doi:10.3969/j.issn.1006-1959.2018.22.041]
点击复制

含卡培他滨方案一线或后线治疗晚期乳腺癌的效果对比()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2018年22期
页码:
142-144
栏目:
药物与临床
出版日期:
2018-11-15

文章信息/Info

Title:
Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy
文章编号:
1006-1959(2018)22-0142-03
作者:
胡平华黄 勤李志华
(南昌市第三医院乳腺肿瘤科,江西 南昌 330000)
Author(s):
HU Ping-huaHUANG QinLI Zhi-hua
(Department of Breast Cancer,the Third Hospital of Nanchang,Nanchang 330000,Jiangxi,China)
关键词:
卡培他滨乳腺癌治疗方案晚期
Keywords:
CapecitabineBreast cancerTreatment regimenAdvanced stage
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2018.22.041
文献标志码:
A
摘要:
目的 对比观察含卡培他滨方案一线或后线治疗晚期乳腺癌的效果。方法 选取2013年1月~2016年2月我院收治的95例晚期乳腺癌患者作为研究对象,按照卡培他滨出现方案分为一线组(27例)、二线组(35例)、三线组(33例),观察其疗效和安全性。结果 治疗效果方面,一线组的完全缓解(CR)、客观有效率(ORR)、临床获益率(CBR)均高于三线组(P<0.05),疾病进展(PD)低于三线组(P<0.05);二线组的PD低于三线组(P<0.05),CBR上高于三线组(P<0.05)。三组安全性比较,差异无统计学意义(P>0.05)。结论 相较于三线方案,一线或二线方案含卡培他滨治疗晚期乳腺癌患者,在控制和缓解患者癌细胞方面具有较好作用;而卡培他滨出现何种方案中并不会增加安全性事件;推荐临床应用一线或二线方案含卡培他滨。
Abstract:
Objective To compare the efficacy of capecitabine regimen in the treatment of advanced breast cancer with first-line or posterior line therapy.Methods 95 patients with advanced breast cancer admitted in our hospital from January 2013 to February 2016 were selected as study subjects.According to capecitabine regimen, the patients were divided into first line group(27 cases), second line group(35 cases) and third line group(33 cases). The efficacy and safety of capecitabine were observed.Results In terms of therapeutic effect,the complete remission (CR),objective efficiency rate (ORR),clinical benefit rate(CBR) of the first group was higher than that in the third line group (P<0.05).The progression of disease (PD) was lower than that of the third line group(P<0.05).The PD of the second line group was lower than that of the third line group(P<0.05) and its CBR was higher than that in the third line group (P<0.05).There was no significant difference in safety among the three groups(P>0.05).Conclusion Compared with the three-line regimen, the first-line or second-line regimen with capecitabine in the treatment of patients with advanced breast cancer,it has a good effect in controlling and relieving cancer cells in patients.And it does not increase security events that which kind of regimen capecitabine was in.It is recommended that the first or second line regimen include capecitabine.

参考文献/References:


[1]Lange JM,Takashima JR,Peterson SM,et al.Breast cancer in female survivors of Wilms tumor: a report from the national Wilms tumor late effects study[J].Cancer,2015,120(23):3722-3730.
[2]江泽飞.腺癌治疗决策:从个体化治疗到精准医学[J].中国实用外科杂志,2015,5(7):697-700.
[3]李伟,马德亮,李燕,等.转移性乳腺癌循环肿瘤细胞检测对化疗疗效的评价[J].中华肿瘤防治杂志,2015,22(24):1889-1893.
[4]Masuda N,Lee SJ,Ohtani S,et al.Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy[J].N Engl J Med,2017,376(22):2147-2159.

相似文献/References:

[1]董 云.SPECT/CT 双时相99mTc- MIBI断层显像 在乳腺癌诊断中的应用[J].医学信息,2018,(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
 DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Medical Information,2018,(22):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[2]李建辉,祝旭龙.乳腺癌的治疗管理——把好生活质量关[J].医学信息,2018,(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[3]石 磊,孙新增,李宝山,等.Ⅱ、Ⅲ期结肠癌患者辅助化疗XELOX方案、FOLFOX方案的临床疗效、不良反应及生活质量对比[J].医学信息,2018,(13):68.[doi:10.3969/j.issn.1006-1959.2018.13.020]
 SHI Lei,SUN Xin-zeng,LI Bao-shan,et al.Clinical Efficacy,Adverse Reactions and Quality of Life of Adjuvant Chemotherapy XELOX and FOLFOX in Patients with Stage II and III Colon Cancer[J].Medical Information,2018,(22):68.[doi:10.3969/j.issn.1006-1959.2018.13.020]
[4]杨玉峰,李 强,曲国红,等.乳腺癌术前巴德枪穿刺检测ER、PR的临床研究[J].医学信息,2018,(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
 YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Medical Information,2018,(22):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[5]刘 曼,厉玛倩倩,徐润润,等.延续性护理对乳腺癌术后化疗患者生活质量与 健康知识水平的影响[J].医学信息,2018,(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
 LIU Man,LIMA Qian-qian,XU Run-run,et al.Effect of Continuous Nursing on Quality of Life and Health Knowledge of Postoperative Chemotherapy Patients with Breast Cancer[J].Medical Information,2018,(22):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
[6]张艳萍,曹 玉,孙国平.服用阿司匹林对乳腺癌患者生存获益的Meta分析[J].医学信息,2018,(20):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
 ZHANG Yan-ping,CAO Yu,SUN Guo-ping.Meta Analysis of the Survival Benefit of Patients with Breast Cancer Treated with Aspirin[J].Medical Information,2018,(22):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
[7]钟 磊,谢海燕,林 霖.电化学发光免疫分析技术检测肿瘤标志物在乳腺癌诊断中的应用[J].医学信息,2018,(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
 ZHONG Lei,XIE Hai-yan,LIN Lin.Application of Electrochemiluminescence Immunoassay for Detection of Tumor Markers in Diagnosis of Breast Cancer[J].Medical Information,2018,(22):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
[8]阙海涛,曹 斌,秦志刚.EGFL7在乳腺癌中的研究进展[J].医学信息,2018,(23):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
 QUE Hai-tao,CAO Bin,QIN Zhi-gang.Research Progress of EGFL7 in Breast Cancer[J].Medical Information,2018,(22):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
[9]张文婧,宋 冰.HER-2阳性乳腺癌分子靶向治疗进展[J].医学信息,2018,(24):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
 ZHANG Wen-jing,SONG Bing.Progress in Molecular Targeted Therapy for HER-2 Positive Breast Cancer[J].Medical Information,2018,(22):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
[10]张 乐,徐胜昔,郭翔取,等.Tyrer-Cuzick模型联合SNPs位点在江西地区乳腺癌诊断中应用研究[J].医学信息,2018,(24):131.[doi:10.3969/j.issn.1006-1959.2018.24.038]
 ZHANG Le,XU Sheng-xi,GUO Xiang-qu,et al.Application of Tyrer-Cuzick Model Combined with SNPs Locus in the Diagnosis of Breast Cancer in Jiangxi Area[J].Medical Information,2018,(22):131.[doi:10.3969/j.issn.1006-1959.2018.24.038]

更新日期/Last Update: 2018-12-03